

## How COVID-19 Infection Associates with Cardiovascular Emergency?

Jin-Yu Che<sup>1</sup>, Ting-Ren Lu<sup>2</sup>, Bin Xu<sup>1</sup> and Da-Yong Lu<sup>1\*</sup>

<sup>1</sup>School of Life Science, Shanghai University, Shanghai, China

<sup>2</sup>College of Science, Shanghai University, Shanghai, China

\*Corresponding Author: Da-Yong Lu, School of Life Science, Shanghai University, Shanghai, China.

Received: January 08, 2021; Published: January 29, 2020

### Abstract

The coronavirus (COVID-19, SARS-Co-2) pandemic is the biggest human health-catastrophic in 2020. The origin and pandemic of COVID-19 sparks many biomedical hypotheses and therapeutic development. The association between cardiovascular emergency and COVID-19 infection is a new frontier for coronavirus pandemic study. Different situations associated with COVID-19 infection are required to counteract with potential cardiovascular emergence in the clinic.

**Keywords:** Obesity; COVID-19; Emergency; Viral Treatment; Inflammatory Factors; Viral Infection

### Background

The coronavirus (COVID-19, SARS-Co-2) pandemic is the biggest human health-catastrophic in 2020 [1-9]. The origin and pandemic of COVID-19 sparks many biomedical hypotheses and therapeutic development. The association between cardiovascular emergency and COVID-19 infection is a new frontier for coronavirus pandemic study.

### Methods

Understanding different situations associated with COVID-19 infection are required to counteract with potential disease emergence in the clinic. Following medical topics are important for future.

#### Coronavirus infection and consequence

- Is it a risk factor for increasing human mortality?
- Does it need some other drug treatment?
- Are there some new pathological pathways by virus infection?

#### COVID-19 infection and other diseases

The pathology pathways leading to human mortality by COVID-19 are largely unknown. A number of clinical pathogenesis has been associated (co-morbidity) [7-9]. Human metabolic abnormal is part of this series of human co-morbidity and potential human mortality [10-15]. Different types of counteractive measures are suitable for different individuals. Apart from life-style and energy limitation, cellular and molecular etiologic/pathological mechanism study may be indispensable [16-18].

### Cardiovascular emergency

Apart from pulmonary injury, COVID-19 also affects other human organs—cardiology, gastrointestinal, neuropathology, kidney and others [19]. COVID-19 may affect human mortality in patients with cardiovascular emergency. Proper diagnosis and analysis of human emergency condition may be a predictive parameter for consequent therapy. It is an open question to exploration.

### Future Direction

Several pathways are important for the future:

- Molecular pathogenesis for cardiovascular emergency associated with viral infection.
- Find the convention and pipeline for drug development.
- Clinical paradigms for overcoming this unfavorable situation.

### Conclusion

Human emergency is strongly associated with human morbidity and mortality. Modern genetic/molecular diagnosis in the clinic is indispensable for therapeutic interventions of COVID-19 infections.

### Conflict of Interests

None.

### Bibliography

1. Zhu N., *et al.* "A novel coronavirus from patients with pneumonia in China". *The New England Journal of Medicine* 382.8 (2020): 727-733.
2. Ciotti M., *et al.* "COVID-19 outbreak: An overview". *Chemotherapy* (2020).
3. Miranda P and Getty AFP. "Coronavirus pandemic, nature's pledge to you". *Nature* 579 (2020): 471-472.
4. Callaway E. "Should scientists infect healthy people with the coronavirus to test vaccines?" *Nature* (2020): 580.
5. Callaway E. "Coronavirus vaccines five key questions as trial begins". *Nature* 578 (2020): 481.
6. Blaising J., *et al.* "Arbidol as a broad-spectrum antiviral: an update". *Antiviral Research* 107 (2014): 84-94.
7. Vincent MJ., *et al.* "Chloroquine is a potent inhibitor of SARS coronavirus infection and spread". *Virology Journal* 2.1 (2005): 69.
8. Kebede T., *et al.* "Potential drug options for treatment of COVID-19, a review". *Coronaviruses* 1.1 (2020): 42-48.
9. Doshi GM., *et al.* "Critical insight into the attributes of emerging novel coronavirus (COVID-19) in India and across the world". *Coronaviruses* 1.1 (2020): 49-56.
10. Lu DY., *et al.* "Type 2 diabetes study, introduction and perspective". *The Open Diabetes Journal* 8 (2018): 13-21.
11. Brestoff JJR and Artis D. "Immune regulation of metabolic homeostasis in health and disease". *Cell* 161 (2015): 146-160.

12. Yanai H. "VLDL is the leading actor in lipid abnormality in patients with diabetes and obesity". *Journal of Endocrinology and Metabolism* 7.4 (2017): 101-102.
13. Putta S., *et al.* "Diabetes mellitus and male aging, pharmacotherapeutics and clinical implications". *Current Pharmaceutical Design* 23.41 (2017): 6321-6346.
14. Che JY., *et al.* "Human obesity and diabetes, is it associated with COVID-19 mortality". *EC Diabetes and Metabolic Research* 4.11 (2020): 1-3.
15. Jainta N., *et al.* "Infection diseases and vaccination in patients with diabetes". *EC Diabetes and Metabolic Research* 3.3 (2019): 91-97.
16. Easton JD., *et al.* "Risk for major bleeding in patients receiving Ticagrelor compared with aspirin after transient ischemic attack or acute ischemic stroke in the SOCRATES study (acute stroke or transient ischemic attack treated with aspirin or Ticagrelor and patient outcome)". *Circulation* 136 (2017): 907-916.
17. Lu DY., *et al.* "Heart and brain stroke, a paramount task for emergency medication". *EC Emergency Medicine and Critical Care* 3.10 (2019): 785.
18. Lu DY., *et al.* "Brain stroke treatment, emergency importance". *EC Emergency Medicine and Clinical Care* 3.11 (2019): 115-117.
19. Naqvi IA and Tazvi SNZ. "The comprehensive appraisal of COVID-19: its clinical panorama from virology till management and beyond". *Coronavirus* 1.1 (2020): 57-72.

**Volume 5 Issue 2 February 2021**

**©All rights reserved by Da-Yong Lu., *et al.***